A study on the safety of a low-protein diet for patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
Not Applicable
- Conditions
- Patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
- Registration Number
- JPRN-UMIN000042609
- Lead Sponsor
- Jichi Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Sarcopenia (AWGS2019) Liver cirrhosis, alcoholic liver damage, autoimmune hepatitis, primary cholangitis, viral hepatitis, Wilson disease, and other liver diseases Severe heart failure, diabetes mellitus, hypertension, interstitial pneumonitis, renal failure, autoimmune diseases, and infections Insulin or steroids use, under hemodialysis Malignant diseases Under other dietary intervention Pregnancy Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety assessments including hypotrophic status (nutritional assessment SGA, blood albumin level, total lymphocyte count, free fatty acids) and sarcopenia (sarcopenia screening items).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link low-protein diets to NAFLD/NASH liver fibrosis regression?
How does low-protein diet compare to GLP-1 receptor agonists in managing NASH fibrosis?
Which biomarkers predict response to low-protein dietary interventions in NAFLD patients?
What are the potential adverse events of low-protein diets in NASH patients with comorbidities?
Are there combination therapies with low-protein diets for NASH treatment in clinical trials?